• 1
    Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003;3:363368.
  • 2
    Negro-Alvarez JM, Miralles-López JC. Chronic idiopathic urticaria treatment. Allergol Immunopathol 2001;29:129132.
  • 3
    O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197201.
  • 4
    Kozel MMA, Sabroe RA. Chronic urticaria. Aetiology, management and current future treatment options. Drugs 2004;64:25152536.
  • 5
    Monroe E. Review of H1 antihistamines in the treatment of chronic idiopathic urticaria. Cutis 2005;76:119126.
  • 6
    Sabroe RA, Greaves MW. Chronic idiopathic urticaria with functional antibodies 12 years on. Br J Dermatol 2006;154:813819.
  • 7
    Asero R, Tedeschi A, Riboldini P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006;117:11131117.
  • 8
    Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CEH, Greaves MW, Henz BM et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006;61:321331.
  • 9
    Petersen LJ, Church MK, Skov PS. Platelet-activating factor induces histamine release from human mast cells in vivo, which is reduced by local nerve blockade. J Allergy Clin Immunol 1997;99:640647.
  • 10
    Prescott SM, Zimmerman GA, McIntyre TM. The production of platelet-activating factor by cultured human endothelial cells: regulation and function. In: SnyderF, editor. Platelet activating factor and related lipid mediators. New York: Plenum Press, 1987:323340.
  • 11
    Merlos M, Giral M, Balsa D, Ferrando Q, Queralt M, Puigdement A et al. Ruptadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997;280:114121.
  • 12
    Barrón S, Ramis I, Garcia-Rafanell J, Merios M. Inhibitory activity of rupatadine on pro-inflammatory cytokine production, relationship with binding affinity. Methods Find Exp Clin Pharmacol 2005;27 (Suppl. ):161162 (abstract).
  • 13
    Juhlin L, Rihoux JP. Effect of ceterizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria. Acta Derm Venereol 1990;70:151152.
  • 14
    Stuebner P, Horak F, Zieglmayer R, Arnaiz E, Leuratti C, Perez I et al. Effects of rupatadine versus placebo on allergen-induced symptoms in patients exposed to aeroallergens in Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2006;96:3744.
  • 15
    Martinez-Cocera C, De Molina M, Marti-Guadano E, Pola J, Conde J, Borja J et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel group study. J Investig Allergol Clin Immunol 2005;15:2229.
  • 16
    Guadaño EM, Serra-Batlles J, Meseguer J, Castillo JA, De Molina M, Valero A et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004;59:766771.
  • 17
    Saint-Martin F, Dumur JP, Perez I, Izquierdo I, French Rupatadine-Rhinitis Study Group. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004;14:3440.
  • 18
    Dubertret L, Zalupca L, Cristodoulo T, Benea V, Medina I, Fantin S et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Eur J Dermatol 2007, in press.
  • 19
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210216.
  • 20
    Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004;93:142146.
  • 21
    Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999;104:10711078.
  • 22
    Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000;84:517522.
  • 23
    Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40:7276.
  • 24
    Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003;48:535541.
  • 25
    Sansom JE, Brooks J, Burton JL, Archer CB. Effects of H1- and H2-antihistamines on platelet-activating factor and bradykinin-induced inflammatory responses in human skin. Clin Exp Dermatol 1996;21:3337.
  • 26
    Jenks PJ, Kavanagh GM, Brooks J, Bradfield JW, Archer CB. Comparison of the wheal and flare responses to platelet activating factor (PAF) and histamine, and the ultrastructural effects of PAF in the skin of atopic and normal subjects. Clin Exp Dermatol 1999;24:112117.
  • 27
    Juhlin L, Pihl-Lundin I. Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. Acta Derm Venerol 1992;72:197200.
  • 28
    Grandel KE, Farr RS, Wanderer AA, Eisenstadt TC, Wasserman SI. Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med 1985;313:405409.
  • 29
    Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CEH, Greaves MW, Henz BM et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006;61:316320.
  • 30
    Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2007;32:3438.